Cargando…

Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved

OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS: A historical cohort study of medical records of...

Descripción completa

Detalles Bibliográficos
Autores principales: da Costa, Josiane Moreira, de Moura, Cristiano Soares, de Pádua, Cristiane Aparecida Menezes, Vegi, Aline Siqueira Fogal, Magalhães, Sérgia Maria Starling, Rodrigues, Marina Barra, Ribeiro, Andréia Queiroz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Saúde Pública da Universidade de São Paulo 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705550/
https://www.ncbi.nlm.nih.gov/pubmed/31432930
http://dx.doi.org/10.11606/s1518-8787.2019053000879
_version_ 1783445610710433792
author da Costa, Josiane Moreira
de Moura, Cristiano Soares
de Pádua, Cristiane Aparecida Menezes
Vegi, Aline Siqueira Fogal
Magalhães, Sérgia Maria Starling
Rodrigues, Marina Barra
Ribeiro, Andréia Queiroz
author_facet da Costa, Josiane Moreira
de Moura, Cristiano Soares
de Pádua, Cristiane Aparecida Menezes
Vegi, Aline Siqueira Fogal
Magalhães, Sérgia Maria Starling
Rodrigues, Marina Barra
Ribeiro, Andréia Queiroz
author_sort da Costa, Josiane Moreira
collection PubMed
description OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS: A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). RESULTS: The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). CONCLUSIONS: The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism.
format Online
Article
Text
id pubmed-6705550
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Faculdade de Saúde Pública da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-67055502019-09-17 Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved da Costa, Josiane Moreira de Moura, Cristiano Soares de Pádua, Cristiane Aparecida Menezes Vegi, Aline Siqueira Fogal Magalhães, Sérgia Maria Starling Rodrigues, Marina Barra Ribeiro, Andréia Queiroz Rev Saude Publica Original Article OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS: A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). RESULTS: The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). CONCLUSIONS: The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism. Faculdade de Saúde Pública da Universidade de São Paulo 2019-08-15 /pmc/articles/PMC6705550/ /pubmed/31432930 http://dx.doi.org/10.11606/s1518-8787.2019053000879 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
da Costa, Josiane Moreira
de Moura, Cristiano Soares
de Pádua, Cristiane Aparecida Menezes
Vegi, Aline Siqueira Fogal
Magalhães, Sérgia Maria Starling
Rodrigues, Marina Barra
Ribeiro, Andréia Queiroz
Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved
title Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved
title_full Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved
title_fullStr Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved
title_full_unstemmed Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved
title_short Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved
title_sort restrictive measure for the commercialization of antimicrobials in brazil: results achieved
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705550/
https://www.ncbi.nlm.nih.gov/pubmed/31432930
http://dx.doi.org/10.11606/s1518-8787.2019053000879
work_keys_str_mv AT dacostajosianemoreira restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved
AT demouracristianosoares restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved
AT depaduacristianeaparecidamenezes restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved
AT vegialinesiqueirafogal restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved
AT magalhaessergiamariastarling restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved
AT rodriguesmarinabarra restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved
AT ribeiroandreiaqueiroz restrictivemeasureforthecommercializationofantimicrobialsinbrazilresultsachieved